ArticleCureus2025
Side Effects of COVID-19 Vaccination Among Medical Students in Bangladesh: A Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Vaccination is a cornerstone of COVID-19 control, yet concerns about side effects continue to influence acceptance. Evidence from medical students in low- and middle-income countries is limited, despite their future role in guiding public attitudes. Methods A cross-sectional online survey was conducted among undergraduate medical students in Bangladesh between February 2021 and April 2022. Data on demographics, vaccination history, and post-vaccination symptoms were collected through a structured questionnaire. Descriptive statistics, chi-square tests, and multivariable Firth logistic regression were used to examine associations between sex, vaccine type, and side effects. Results Of 305 respondents (mean age = 21.6 years; 196 females, 64.3%), 293 (96.1%) and 286 (93.8%) received the first and second vaccine doses, respectively, while 191 (62.6%) received a third dose. The most common vaccines were Sinopharm (125 participants, 41.0%), Pfizer-BioNTech (68 participants, 22.3%), and Moderna (60 participants, 19.7%). Overall, 276 participants (90.5%) experienced at least one side effect, with the prevalence declining across doses: 270 (88.5%) after the first dose, 243 (79.7%) after the second dose, and 128 (42.0%) after the third dose. The most frequent complaints were local pain (508 cases, 41.2%), fever (184, 14.9%), rash or itch (114, 9.2%), headache (108, 8.8%), and myalgia (103, 8.3%). Less common outcomes included anxiety or low mood (70, 5.7%) and alopecia (45, 3.6%), while serious events were rare. Female participants had higher odds of experiencing second-dose side effects (OR: 1.85, 95% CI: 1.05-3.26). Compared with Moderna, Pfizer-BioNTech was associated with fewer third-dose events (OR: 0.45, 95% CI: 0.21-0.94). Conclusion COVID-19 vaccines were well-tolerated among Bangladeshi medical students, with most side effects mild and self-limiting. Reactogenicity declined with subsequent doses and varied by sex and vaccine type. These results emphasize the need for transparent communication and vaccine literacy within medical education to enhance students' confidence and their role in addressing vaccine hesitancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.